Skip to main content

Table 1 Demographic data and clinical scenario before ECMO implantation of patients undergoing ECMO for cardiogenic shock

From: Does lactate clearance prognosticates outcomes in ECMO therapy: a retrospective observational study

 

All (n = 48)

Survivors (n = 14)

Non-survivors (n = 34)

p-value*

Age (Years)

54 ± 13

47 ± 11

57 ± 12

0.006

Gender (Male)

31 (64.6%)

10 (71.4%)

21 (61.8%)

0.535

ECMO support indications

 Postcardiotomy cardiogenic shock

26 (54.2%)

8 (57.1%)

18 (52.9%)

0.823

 Cardiac arrest

15 (31.3%)

4 (28.6%)

11 (32.4%)

 Decompensated cardiomyopathy

7 (14.6%)

2 (14.3%)

5 (14.7%)

  1. Subgroups (The survivors versus Non-the survivors) refer to 30-day mortality. p-values calculated for comparison of the survivors versus non-the survivors by statistical analysis
  2. Data are mean ± SD or n (%)
  3. *Determined by Mann-Whitney U test or Spearman’s rho test
  4. Abbreviations: ECMO extracorporeal membrane oxygenation
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us